Indications
Denosis is a RANK ligand (RANKL) inhibitor. It is used in the following conditions. Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture: Denosis is indicated for postmenopausal women with osteoporosis who are at high risk for fracture. High risk means a history of osteoporotic fracture, or multiple risk factors for fracture. It also covers patients who have failed or can't tolerate other available osteoporosis therapy. In these women, Denosis reduces the incidence of vertebral, nonvertebral and hip fractures. Treatment to Increase Bone Mass in Men with Osteoporosis: Denosis is indicated to increase bone mass in men with osteoporosis at high risk for fracture. High risk is defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or failure of, or intolerance to, other available osteoporosis therapy. Treatment of Glucocorticoid-Induced Osteoporosis: Denosis is indicated for men and women at high risk of fracture who are starting or continuing systemic glucocorticoids at a daily dose equivalent to 7.5 mg or more of prednisone, and who are expected to stay on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of, or intolerance to, other available osteoporosis therapy. Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Denosis is indicated to increase bone mass in men at high risk for fracture who are receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Denosis also reduced the incidence of vertebral fractures. Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer: Denosis is indicated to increase bone mass in women at high risk for fracture who are receiving adjuvant aromatase inhibitor therapy for breast cancer. Treatment of Multiple Myeloma and Bone Metastasis from Solid Tumors: Denosis is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Treatment of Giant Cell Tumor of Bone: Denosis is indicated for adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable, or where surgical resection is likely to result in severe morbidity. Treatment of Hypercalcemia of Malignancy: Denosis is indicated for hypercalcemia of malignancy that is refractory to bisphosphonate therapy.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL. It binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. By binding RANKL, denosumab prevents it from activating its receptor, RANK, on the surface of osteoclasts and their precursors. This blocks the RANKL/RANK interaction, inhibiting osteoclast formation, function, and survival. As a result, bone resorption decreases while bone mass and strength increase in both cortical and trabecular bone.
Pregnancy & Breastfeeding
Pregnant women and females of reproductive potential: Denosumab may cause fetal harm when given during pregnancy. Females of reproductive potential should be advised to use effective contraception during treatment and for at least 5 months after the last dose of Denosumab.
Lactation: Whether to breastfeed while using Denosumab should take into account the developmental and health benefits of breastfeeding, the mother's clinical need for Denosumab treatment, and any potential adverse effects on the breastfed child from Denosumab itself or from the underlying maternal condition.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.